Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 1, 2014, Pages 249-254

  Yang, Chunzhang ^a   Swallows, Cody L ^a   Zhang, Chao ^a   Lu, Jie ^a   Xiao, Hongbin ^b   Brady, Roscoe O ^a   Zhuang, Zhengping ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b INSTITUTE OF CHINESE MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BAG FAMILY CHAPERONE REGULATOR 3; CARRIER PROTEINS AND BINDING PROTEINS; CELASTROL; CELL CYCLE PROTEIN 37; CHAPERONE; GLUCOSYLCERAMIDASE; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; ENZYME ACTIVITY; FIBROBLAST; GAUCHER DISEASE; HEAT SHOCK RESPONSE; HELA CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROCESSING; TRANSCRIPTION INITIATION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CATALYSIS; CELL CYCLE PROTEINS; CHAPERONINS; FIBROBLASTS; GAUCHER DISEASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCOSYLCERAMIDASE; HELA CELLS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; MUTATION; PLANT PREPARATIONS; PROTEIN BINDING; PROTEIN DENATURATION; PROTEIN FOLDING; REAL-TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRITERPENES;

EID: 84891929380     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1321341111     Document Type: Article

References (54)

1. Brady RO, Kanfer JN, Shapiro D (1965) Metabolism of Glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. BiochemBiophys Res Commun 18: 221-225.
2. Brady RO, Kanfer JN, Bradley RM, Shapiro D (1966) Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease. J Clin Invest 45(7): 1112-1115.
3. Mistry PK, et al. (1992) Genetic diagnosis of Gaucher's disease. Lancet 339(8798): 889-892.
4. Horowitz M, Zimran A (1994) Mutations causing Gaucher disease. Hum Mutat 3(1): 1-11.
5. Stone DL, et al. (2000) Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease. Hum Mutat 15(2): 181-188.
6. Lu J, et al. (2010) Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl. Proc Natl Acad Sci USA 107(50): 21665-21670.
7. Ron I, Horowitz M (2005) ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet 14(16): 2387-2398.
8. Zheng W, et al. (2007) Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci USA 104(32): 13192-13197.
9. Trott A, et al. (2008) Activation of heat shock and antioxidant responses by the natural product celastrol: Transcriptional signatures of a thiol-targeted molecule. Mol Biol Cell 19(3): 1104-1112.
10. Sethi G, Ahn KS, Pandey MK, Aggarwal BB (2007) Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 109(7): 2727-2735.
11. Chang FR, et al. (2003) Antitumor agents. 228. five new agarofurans, Reissantins A-E, and cytotoxic principles from Reissantia buchananii. J Nat Prod 66(11): 1416-1420.
12. Nagase M, et al. (2003) Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem 67(9): 1883-1887.
13. Yang H, Chen D, Cui QC, Yuan X, Dou QP (2006) Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 66(9): 4758-4765.
14. Walcott SE, Heikkila JJ (2010) Celastrol can inhibit proteasome activity and upregulate the expression of heat shock protein genes, hsp30 and hsp70, in Xenopus laevis A6 cells. Comp Biochem Physiol A Mol Integr Physiol 156(2): 285-293.
15. Mu TW, et al. (2008) Chemical and biological approaches synergize to ameliorate protein-folding diseases. Cell 134(5): 769-781.
16. Zhang T, et al. (2008) A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7(1): 162-170.
17. Zhang T, et al. (2009) Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem 284(51): 35381-35389.
18. Lu J, et al. (2011) Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease. Proc Natl Acad Sci USA 108(52): 21200-21205.
19. Yang C, et al. (2013) Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones. Proc Natl Acad Sci USA 110(3): 966-971.
20. Bendikov-Bar I, Ron I, Filocamo M, Horowitz M (2011) Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. Blood Cells Mol Dis 46(1): 4-10.
21. Bendikov-Bar I, Horowitz M (2012) Gaucher disease paradigm: From ERAD to comorbidity. Hum Mutat 33(10): 1398-1407.
22. Ong DS, Kelly JW (2011) Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases. Curr Opin Cell Biol 23(2): 231-238.
23. Westerheide SD, et al. (2004) Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 279(53): 56053-56060.
24. Westerheide SD, Morimoto RI (2005) Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem 280(39): 33097-33100.
25. Vos MJ, Hageman J, Carra S, Kampinga HH (2008) Structural and functional diversities between members of the human HSPB, HSPH, HSPA, and DNAJ chaperone families. Biochemistry 47(27): 7001-7011.
26. Hageman J, et al. (2010) A DNAJB chaperone subfamily with HDAC-dependent activities suppresses toxic protein aggregation. Mol Cell 37(3): 355-369.
27. Takayama S, Reed JC (2001) Molecular chaperone targeting and regulation by BAG family proteins. Nat Cell Biol 3(10): E237-E241.
28. Doong H, et al. (2003) CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: Accumulation of poly-ubiquitinated Hsp90 client proteins. J Biol Chem 278(31): 28490-28500.
29. Gamerdinger M, et al. (2009) Protein quality control during aging involves recruitment of the macroautophagy pathway by BAG3. EMBO J 28(7): 889-901.
30. Ammirante M, et al. (2010) IKKgamma protein is a target of BAG3 regulatory activity in human tumor growth. Proc Natl Acad Sci USA 107(16): 7497-7502.
31. Brady RO, Yang C, Zhuang Z (2013) An innovative approach to the treatment of Gaucher disease and possibly other metabolic disorders of the brain. J Inherit Metab Dis 36(3): 451-454.
32. Breinig M, et al. (2009) Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma. Hepatology 50(1): 102-112.
33. Caldas-Lopes E, et al. (2009) Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci USA 106(20): 8368-8373.
34. Cerchietti LC, et al. (2009) A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med 15(12): 1369-1376.
35. Huntoon CJ, et al. (2010) Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway. Cancer Res 70(21): 8642-8650.
36. Marubayashi S, et al. (2010) HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 120(10): 3578-3593.
37. Usmani SZ, Bona RD, Chiosis G, Li Z (2010) The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J Hematol Oncol 3:40.
38. Chen W, Sin SH, Wen KW, Damania B, Dittmer DP (2012) Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog 8(11):e1003048.
39. Moulick K, et al. (2011) Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol 7(11): 818-826.
40. Beutler E, Dale GL, Guinto DE, Kuhl W (1977) Enzyme replacement therapy in Gaucher's disease: Preliminary clinical trial of a new enzyme preparation. Proc Natl Acad Sci USA 74(10): 4620-4623.
41. Brady RO (2006) Enzyme replacement for lysosomal diseases. Annu Rev Med 57: 283-296.
42. Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36(4): 305-315.
43. Egorin MJ, et al. (1998) Metabolism of 17-(allylamino)-17- demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res 58(11): 2385-2396.
44. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R (2007) FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12(10): 1247-1252.
45. Wang S, Liu K, Wang X, He Q, Chen X (2011) Toxic effects of celastrol on embryonic development of zebrafish (Danio rerio). Drug Chem Toxicol 34(1): 61-65.
46. Fukutomi A, et al. (2012) A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors. Invest New Drugs 30(3): 1096-1106.
47. Kusy S, Ghosn EE, Herzenberg LA, Contag CH (2012) Development of B cells and erythrocytes is specifically impaired by the drug celastrol in mice. PLoS ONE 7(4):e35733.
48. Lu J, et al. (2013) Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury. Proc Natl Acad Sci USA 110(26): 10747-10752.
49. Festa M, et al. (2011) BAG3 protein is overexpressed in human glioblastoma and is a potential target for therapy. Am J Pathol 178(6): 2504-2512.
50. Rosati A, et al. (2012) Role of BAG3 protein in leukemia cell survival and response to therapy. Biochim Biophys Acta 1826(2): 365-369.
51. Zhu H, Liu P, Li J (2012) BAG3: A new therapeutic target of human cancers? Histol Histopathol 27(3): 257-261.
52. Shiran A, Brenner B, Laor A, Tatarsky I (1993) Increased risk of cancer in patients with Gaucher disease. Cancer 72(1): 219-224.
53. Yang C, et al. (2013) Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas. Blood 121(13): 2563-2566.
54. Yang C, Huntoon K, Ksendzovsky A, Zhuang Z, Lonser RR (2013) Proteostasis modulators prolong missense VHL protein activity and halt tumor progression. Cell Rep 3(1): 52-59.